Metastatic Pancreatic Adenocarcinoma Clinical Trial
— PANTAX-IbOfficial title:
An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | May 15, 2022 |
Est. primary completion date | March 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patients are required to meet all of the following criteria for enrollment into the study: 1. Ability to understand and willingness to provide written informed consent before any trial-related activities. 2. Age 18 years or older. 3. Histologically or cytologically verified pancreatic adenocarcinoma. 4. Inoperable localized, locally advanced or metastatic pancreatic cancer, not amenable for curatively intended treatment, in patients who are to be treated with gemcitabine and nab-paclitaxel. 5. Measurable or non-measurable disease determined by CT scan or MRI, according to RECIST 1.1. 6. Performance status of ECOG = 2 and expected to tolerate the standard recommended (100%) gemcitabine and nab-paclitaxel dose. 7. Recovered to Grade 1 or less from prior surgery or acute toxicities of prior radiotherapy or treatment with cytotoxic or biologic agents. 8. = 2 weeks must have elapsed since any prior surgery or radiotherapy. 9. Adequate conditions as evidenced by the following clinical laboratory values: - Absolute neutrophils count (ANC) = 1.5 x 109/L - Haemoglobin = 6.0 mmol/L - Platelets = 100 x 109 /L - Alanine aminotransferase (ALT) = 2.5 x ULN and aspartate aminotransferase (AST) = 2.5 x ULN* - Total Serum bilirubin = 1.0 ULN - Alkaline phosphatase = 2.5 x ULN* - Creatinine = 1.5 ULN - eGFR within normal limits - Adequate blood clothing function as defined by the International Normalized Ratio (INR) = 1.2 10. Life expectancy longer than 3 months. 11. Sexually active males and females of child-producing potential must use highly effective contraception (intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)) for the study duration and at least 6 months after the last dose of study drug. 12. Signed informed consent. *AST is not mandatory. In case of known liver metastases with ALT and AST = 5 x ULN and/or alkaline phosphatase = 5 x ULN: Patients who do not conform to the transaminase and/or alkaline phosphatase inclusion criteria, but who by the PI are considered in good PS and otherwise eligible for inclusion, and where the transaminase and/or alkaline phosphatase levels are considered elevated due to other reasons than deteriorated lever capacity, may be considered for inclusion based on conferred agreement between PI and sponsor. Exclusion Criteria: Patients meeting any of the following criteria will be excluded from enrollment: 1. Concurrent chemotherapy, radiotherapy, or other investigational drug during study period. 2. Previous surgeries with resection of the complete stomach or greater part of small intestines (excluding the duodenum), whereby absorption of SCO-101 may be affected. Treatment with Creon or similar is allowed. 3. Difficulty in swallowing tablets. 4. CNS metastases requiring steroids. 5. Treatment with antibiotics for infections or with clinical symptoms of active infection. Patients showing symptoms of CoViD19 must be tested for active CoViD19 infection. 6. Known HIV positivity. 7. Known active hepatitis B or C. 8. Clinically significant (i.e. active) cardiovascular disease: - Stroke, Transient ischemic attack (TIA) or myocardial infarction within = 6 months prior to day 1. - Unstable angina or NYHA Grade II or greater congestive heart failure (CHF). - Serious cardiac arrhythmia requiring medication. 9. Mental status, symptomatic epilepsy or other CNS disease where the investigator assesses the patient not fit for the clinical study. 10. Other medications or conditions that in the Investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results. Other severe medical conditions, including serious heart disease, unstable diabetes, uncontrolled hypercalcemia or previous organ transplants. Participation in another clinical trial with experimental medication within 30 days prior to registration. 11. Known hypersensitivity to gemcitabine and/or nab-paclitaxel. 12. Pregnant women or women who are breastfeeding. 13. Prior or present neuropathy > grade I (NCI-CTCAE v.5.0). 14. Curatively intended treatment. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aalborg University Hospital | Aalborg | |
Denmark | Odense Universitetshospital | Odense | |
Germany | Catholic Hospital Bochum - St. Josef-Hospital | Bochum | |
Germany | University Hospital Of Ulm | Ulm |
Lead Sponsor | Collaborator |
---|---|
Scandion Oncology A/S | Alcedis GmbH |
Denmark, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Novel predictive biomarker feasibility | assessment of biomarkers from blood and tumor | assessed from first administration to end of treatment, assessed up to 100 months. | |
Primary | Safety and Tolerability | Safety and tolerability by assessing the number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until four weeks after end of treatment to evaluate safety of SCO-101 in combination with gemcitabine and nab-paclitaxel determined according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE v.5.0). | Through study completion, assessed up to 100 months | |
Primary | Maximum Tolerated Dose | To determine the Maximum Tolerated Dose (MTD) of SCO-101 in combination with gemcitabine and nab-Paclitaxel by assessment of Dose Limiting Toxicities (DLT) to SCO-101. | At the end of Cycle 1 (each cycle is 28 days) | |
Secondary | Objective Response Rate | defined as CR and PR using the RECIST v. 1.1 | Tumor assessment is performed every two treatment cycles (2 months), assessed up to 100 months. | |
Secondary | Clinical Benefit Rate (CBR) | defined as the number of patients obtaining CR, PR, or SD > 16 weeks according to RECIST v.1.1. | From benefit (CR, PR or SD > 16 weeks) to progression, assessed up to 100 months | |
Secondary | Progression Free Survival (PFS) | defined as time in months from the date of first study treatment with SCO-101 to the date of disease progression or death from any cause, whichever comes first. | From first dosing to progression, assessed up to 100 months | |
Secondary | Overall Survival | defined as time in months from the date of first study treatment to the date of death | through study completion, assessed up to 100 months | |
Secondary | Pharmacokinetic profile | Pharmacokinetic profile of SCO-101 alone and in combination with gemcitabine and nab-paclitaxel | during the first 14 treatment days in the first treatment cycle. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01964287 -
First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.
|
Phase 1/Phase 2 | |
Completed |
NCT02826486 -
Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
|
Phase 2 | |
Active, not recruiting |
NCT04524702 -
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02890355 -
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04132505 -
Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT00998322 -
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04514497 -
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT02562898 -
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
Completed |
NCT01896869 -
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03337087 -
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02677038 -
Olaparib in Treating Patients With Stage IV Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02985125 -
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05383352 -
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
|
Phase 1 | |
Completed |
NCT03943667 -
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02436668 -
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
|
Phase 3 | |
Completed |
NCT01360853 -
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
|
Phase 3 | |
Completed |
NCT01124786 -
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
|
Phase 2 | |
Active, not recruiting |
NCT01585805 -
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 |